PUBLISHER: TechSci Research | PRODUCT CODE: 1886542
PUBLISHER: TechSci Research | PRODUCT CODE: 1886542
Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Chemotherapy, By Region, and Competition, 2020-2030F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global Acute Myeloid Leukemia Market, valued at USD 1.56 Billion in 2024, is projected to experience a CAGR of 8.90% to reach USD 2.63 Billion by 2030. Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the uncontrolled proliferation of abnormal myeloid blast cells. The market for AML therapies is primarily driven by the increasing global incidence of this disease, coupled with an expanding geriatric population which faces a higher risk of diagnosis.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 1.56 Billion |
| Market Size 2030 | USD 2.63 Billion |
| CAGR 2025-2030 | 8.90% |
| Fastest Growing Segment | Hormonal therapy |
| Largest Market | North America |
Key Market Drivers
The global Acute Myeloid Leukemia market is significantly propelled by continuous advancements in AML research and therapeutic technologies. These innovations expand treatment options and improve patient outcomes through novel drug classes and therapeutic strategies. For instance, according to The Leukemia & Lymphoma Society, in December 2024, the U. S. Food and Drug Administration approved revumenib, the first-in-class menin inhibitor for adults and children with advanced acute myeloid leukemia presenting KMT2A gene translocations.
Key Market Challenges
The substantial cost associated with advanced therapeutic regimens presents a significant impediment to the growth of the Global Acute Myeloid Leukemia Market. These high expenses directly affect patient access to potentially life-saving treatments, thereby limiting the overall uptake and revenue potential of innovative therapies. Advanced options, such as novel targeted agents and allogeneic stem cell transplantation, carry considerable price tags that can strain healthcare systems and individual patient finances globally.
Key Market Trends
The increasing utilization of oral and outpatient treatment regimens is significantly reshaping the global Acute Myeloid Leukemia market by enhancing patient convenience and reducing the burden on hospital infrastructure. These innovative approaches enable treatment administration in less restrictive settings, improving the quality of life for patients, particularly the elderly or those with comorbidities.
Key Market Players
- Bristol-Myers Squibb Company (Celgene Corporation)
- Novartis AG
- Genmab AS
- Otsuka Holdings Co. Ltd
- Sanofi-Aventis (Genzyme Corporation)
- Teva Pharmaceutical (Cephalon Inc.)
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Sunesis Pharmaceuticals Inc.
- Astellas Pharma
- Oncolyze Inc.
Report Scope:
In this report, the Global Acute Myeloid Leukemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Acute Myeloid Leukemia Market, By Chemotherapy:
- Cytarabine
- Anthracycline Drugs
- Alkylating Agents
- Anti-metabolites
- Tyrosine Kinase Inhibitors
- Hormonal therapy
- Other chemotherapies
Acute Myeloid Leukemia Market, By Region:
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- South America
- Brazil
- Argentina
- Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Acute Myeloid Leukemia Market.
Available Customizations:
Global Acute Myeloid Leukemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Acute Myeloid Leukemia Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal therapy, Other chemotherapies)
- 5.2.2. By Region
- 5.2.3. By Company (2024)
- 5.3. Market Map
6. North America Acute Myeloid Leukemia Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Chemotherapy
- 6.2.2. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Acute Myeloid Leukemia Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Chemotherapy
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Acute Myeloid Leukemia Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Chemotherapy
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Acute Myeloid Leukemia Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Chemotherapy
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Acute Myeloid Leukemia Market Outlook
7. Europe Acute Myeloid Leukemia Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Chemotherapy
- 7.2.2. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Acute Myeloid Leukemia Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Chemotherapy
- 7.3.1.1. Market Size & Forecast
- 7.3.2. France Acute Myeloid Leukemia Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Chemotherapy
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Acute Myeloid Leukemia Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Chemotherapy
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Acute Myeloid Leukemia Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Chemotherapy
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Acute Myeloid Leukemia Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Chemotherapy
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Acute Myeloid Leukemia Market Outlook
8. Asia Pacific Acute Myeloid Leukemia Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Chemotherapy
- 8.2.2. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China Acute Myeloid Leukemia Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Chemotherapy
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Acute Myeloid Leukemia Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Chemotherapy
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Acute Myeloid Leukemia Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Chemotherapy
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Acute Myeloid Leukemia Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Chemotherapy
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Acute Myeloid Leukemia Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Chemotherapy
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Acute Myeloid Leukemia Market Outlook
9. Middle East & Africa Acute Myeloid Leukemia Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Chemotherapy
- 9.2.2. By Country
- 9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Acute Myeloid Leukemia Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Chemotherapy
- 9.3.1.1. Market Size & Forecast
- 9.3.2. UAE Acute Myeloid Leukemia Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Chemotherapy
- 9.3.2.1. Market Size & Forecast
- 9.3.3. South Africa Acute Myeloid Leukemia Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Chemotherapy
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Saudi Arabia Acute Myeloid Leukemia Market Outlook
10. South America Acute Myeloid Leukemia Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Chemotherapy
- 10.2.2. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Acute Myeloid Leukemia Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Chemotherapy
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Colombia Acute Myeloid Leukemia Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Chemotherapy
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Argentina Acute Myeloid Leukemia Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Chemotherapy
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil Acute Myeloid Leukemia Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Global Acute Myeloid Leukemia Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. Bristol-Myers Squibb Company (Celgene Corporation)
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
- 15.2. Novartis AG
- 15.3. Genmab AS
- 15.4. Otsuka Holdings Co. Ltd
- 15.5. Sanofi-Aventis (Genzyme Corporation)
- 15.6. Teva Pharmaceutical (Cephalon Inc.)
- 15.7. Pfizer Inc.
- 15.8. F. Hoffmann-La Roche Ltd
- 15.9. Sunesis Pharmaceuticals Inc.
- 15.10. Astellas Pharma
- 15.11. Oncolyze Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
